High-Level mRNA of Excision Repair Cross-Complementation Group 1 Gene Is Associated With Poor Outcome of Platinum-Based Doublet Chemotherapy of Advanced Nonsmall Cell Lung Cancer Patients

By Ren Shengxiang   Zhou Songwen   Zhang Ling   Xu Jianfang   Lv Meijun   Zhang Jie   Zhou Caicun   Zhang Jie  

Cancer Investigation, Vol. 28, Iss. 10, 2010-11 ,pp. : 1078-1083

Informa Healthcare

Access to resources Recommend Favorite

Rapidly Alternating Combination of Cisplatin-based Chemotherapy and Hyperfractionated Accelerated Radiotherapy in Split Course for Stage IIIA and Stage IIIB Non-small Cell Lung Cancer: Results of a Phase I-II Study by the GOTHA Group

By Alberto P.   Mirimanoff R.O.   Mermillod B.   Leyvraz S.   Nagy-Mignotte H.   Bolla M.   Wellmann D.   Moro D.   Brambilla E.  

European Journal of Cancer, Vol. 31, Iss. 3, 1995-01 ,pp. : 342-348

Elsevier

Access to resources Recommend Favorite

Analysis of ERCC1, BRCA1, RRM1 and TUBB3 as predictors of prognosis in patients with non-small cell lung cancer who received cisplatin-based adjuvant chemotherapy: A prospective study

By            

Oncology Letters, Vol. 11, Iss. 1, 2016-01 ,pp. : 299-305

Spandidos Publications

Access to resources Recommend Favorite

Association between epidermal growth factor receptor mutations and the expression of excision repair cross-complementing protein 1 and ribonucleotide reductase subunit M1 mRNA in patients with non-small cell lung cancer

By  

Experimental and Therapeutic Medicine, Vol. 9, Iss. 3, 2015-01 ,pp. : 880-884

Spandidos Publications

Access to resources Recommend Favorite

A multi-institutional phase II study of combination chemotherapy with S-1 plus cisplatin in patients with advanced non-small cell lung cancer

By                                  

Oncology Letters, Vol. 2, Iss. 3, 2011-01 ,pp. : 465-470

Spandidos Publications

Access to resources Recommend Favorite